Derma Sciences

Derma Sciences is a Medical Devices company specializing in the field of Advanced Wound Care. Currently their major products are Medihoney, Algicell AG, Xtrasorb wound dressing, Bioguard and Mobility1. Their newest product DSC127 - an Angiotensin Analog - is currently in Phase II Pre-Clinical trials.
Company Growth (employees)
Type
Public
HQ
Princeton, US
Size (employees)
260 (est)
Derma Sciences is headquartered in Princeton, US

Key People at Derma Sciences

John E. Yetter

John E. Yetter

CFO & Vice President of Finance
Srini Conjeevaram

Srini Conjeevaram

Director

Derma Sciences Office Locations

Derma Sciences has offices in Princeton and New York
Princeton, US (HQ)
300 214 Carnegie Center
New York, US
800 3rd Ave

Derma Sciences Data and Metrics

Derma Sciences Financial Metrics

Derma Sciences's revenue was reported to be $84.5 m in FY, 2015 which is a 1% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2015)

84.5 m

Revenue growth (FY, 2014 - FY, 2015), %

1%

Gross profit (FY, 2015)

32.7 m

Gross profit margin (FY, 2015), %

39%

Net income (FY, 2015)

(38.1 m)

EBIT (FY, 2015)

(22 m)

Market capitalization (23-Feb-2017)

197.9 m

Closing share price (23-Feb-2017)

7

Cash (31-Dec-2015)

15.8 m
Derma Sciences's current market capitalization is $197.9 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015

Revenue

79.7 m83.7 m84.5 m

Revenue growth, %

5%1%

Cost of goods sold

50.3 m53.6 m51.7 m

Gross profit

29.4 m30.1 m32.7 m

Gross profit Margin, %

37%36%39%

R&D expense

11.3 m19.3 m807.1 k

General and administrative expense

42 m51 m51.4 m

Operating expense total

53.4 m70.2 m54.7 m

EBIT

(24 m)(40.1 m)(22 m)

EBIT margin, %

(30%)(48%)(26%)

Income tax expense

160.1 k(151 k)(2.2 m)

Net Income

(24 m)(39.8 m)(38.1 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015

Cash

6.5 m19.4 m15.8 m

Accounts Receivable

7.3 m8.8 m8.1 m

Inventories

16.5 m13.3 m20.7 m

Current Assets

49.5 m100.8 m71.1 m

Goodwill

13.5 m13.5 m13.5 m

Total Assets

88.6 m139.3 m114.8 m

Accounts Payable

4.5 m5.1 m2.5 m

Current Liabilities

9.5 m11.5 m13.5 m

Additional Paid-in Capital

140.1 m228.3 m234.9 m

Retained Earnings

(64.2 m)(103.9 m)(142 m)

Total Equity

77.1 m125.6 m98.4 m

Financial Leverage

1.1 x1.1 x1.2 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015

Net Income

(24 m)(39.8 m)(38.1 m)

Accounts Receivable

(266.8 k)(1.4 m)324.2 k

Inventories

(3 m)2.6 m(9.1 m)

Accounts Payable

574.3 k679.9 k(1.6 m)

Cash From Operating Activities

(17.2 m)12.9 m(3.6 m)

Cash From Investing Activities

(20.3 m)(43.9 m)29.2 m

Cash From Financing Activities

2.6 m82.6 m1.8 m

Interest Paid

8937.8 k189
Numbers are in $, USDY, 2015

Revenue/Employee

302.2 k

Financial Leverage

1.2 x

Derma Sciences Operating Metrics

FY, 2015

Patents (US)

50

Derma Sciences Market Value History

Derma Sciences Revenue Breakdown

Derma Sciences Online and Social Media Presence

Derma Sciences News and Updates

Derma Sciences Company Life and Culture

You may also be interested in